NICE rejects Ozanimod (Zeposia) for RRMS

Posted in Industry News on 26th Jan 2021

NICE has made an initial decision not to recommend ozanimod (Zeposia) as an NHS treatment in England and Wales.

NICE acknowledges that ozanimod reduces the number of relapses and brain lesions compared to beta interferon (Avonex), but have asked the manufacturer for more detailed evidence and analysis of the data on disability progression. You can read the draft recommendation at https://www.nice.org.uk/guidance/gid-ta10299/documents/129news

Comments on the draft recommendation can be made through the NICE website https://www.nice.org.uk/consultations/1204/2/recommendations  by 5pm, 12 February 2021.

A final decision is expected to be published later this year.